Emalex Biosciences
Tim Rudolphi is an accomplished executive in the biotechnology and pharmaceuticals sector, currently serving as Chief Commercial Officer at Emalex Biosciences, where the focus is on developing innovative treatments for central nervous system movement disorders. Prior experience includes leading metaMe Health as CEO, directing efforts to revolutionize gastrointestinal disorder treatments through Prescription Digital Therapeutics. Tim founded Plextrad Partners, providing strategic consulting for biotech and pharmaceutical companies. Previous roles at Aprecia Pharmaceuticals and Takeda Pharmaceuticals encompass senior leadership positions overseeing sales, business development, and marketing strategies, managing significant teams, budgets, and product launches. Tim holds a Bachelor of Science degree in Human Anatomy from the University of Illinois Urbana-Champaign and an MBA in Finance from Marquette University.
This person is not in any teams
Emalex Biosciences
Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.